Uncategorized Archives - Page 7 of 7 - Fennec Pharmaceuticals : Fennec Pharmaceuticals

FENNEC TO PRESENT AT THE 2019 CANTOR GLOBAL HEALTHCARE CONFERENCE ON OCTOBER 4, 2019

Posted on October 2, 2019 (October 1, 2019) by mgowland

Research Triangle Park, NC, October 2, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that Rosty Raykov, Chief Executive Officer of Fennec, will present at the Cantor […]

FENNEC APPOINTS JODI A. COOK, PhD TO ITS BOARD OF DIRECTORS

Posted on September 24, 2019 (September 23, 2019) by mgowland

Research Triangle Park, NC, September 24, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has appointed Jodi A. Cook, PhD to its board of directors. […]

FENNEC APPOINTS SHUBH GOEL AS CHIEF COMMERCIAL OFFICER

Posted on September 9, 2019 (September 6, 2019) by mgowland

Seasoned commercial leader to lead the anticipated launch of PEDMARKTM Research Triangle Park, NC, September 9, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has […]

Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results

Posted on August 9, 2019 (August 8, 2019) by mgowland

Anticipate PEDMARK™ New Drug Application (NDA) completion by early 2020 Strong financial position with $17.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention […]

FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING

Posted on June 19, 2019 (June 19, 2019) by mgowland

Research Triangle Park, NC — (Marketwired) – June 18, 2019 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2019 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General […]

Fennec Provides Business Update and Announces First Quarter 2019 Financial Results

Posted on May 9, 2019 by mgowland

Fennec Provides Business Update and Announces First Quarter 2019 Financial Results Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020 Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty […]